ABSTRACT
INTRODUCTION
Previous studies have demonstrated that antigen encapsulation by α 2 -macroglobulin (α 2 M) 1 enhances antigen-specific immune responses, both in vitro and in vivo [1] [2] [3] [4] [5] [6] [7] . For these studies, α 2 M-encapsulated antigen complexes were typically prepared by in vitro incubation of amine-activated α 2 M, designated α 2 M * , with an 8 to 100-fold-molar excess of antigen in the presence of heat [3, 4, 7] . These α 2 M * -antigen complexes were then purified by size-exclusion chromatography to remove unbound antigen. While producing α 2 M * -antigen complexes is not extremely difficult on a small scale, it would be more challenging to produce the complexes and perform the necessary quality control on an industrial scale.
While the maximal incorporation of antigen into α 2 M * occurs following 24 h of incubation at 37˚C, some incorporation of antigen occurs at much earlier time periods [8, 9] . It is thought that α 2 M * -encapsulation occurs naturally in vivo as a mechanism of targeting antigen for uptake, processing, and presentation by professional antigen presenting cells [1] . It, however, is unknown whether in vivo α 2 M * -encapsulation could be promoted in the setting of a vaccine that co-delivers α 2 M * with unbound antigen. A high local concentration of antigen may be necessary to drive incorporation into α 2 M * . Because most routes of injection result in rapid dissipation of antigen, conditions that result in a depot effect, for example intradermal injection and alum absorption, should promote α 2 M * -encapsulation in vivo. In this study, we investigate the ability of α 2 M * , co-administered with unbound antigen, to enhance antigen-specific immune responses through in vivo encapsulation, resulting in enhanced antigen delivery.
MATERIALS AND METHODS

Purification and Activation of Murine and Human α 2 M
Purification and amine-activation of murine α 2 M was performed as previously described [7, 8, 10, 11] . Human α 2 M was purified from fresh, frozen human plasma, obtained from the American Red Cross (Durham, NC, USA), according to a previously published protocol [12] .
Native human α 2 M was converted to the "amine-activated" form (α 2 M * ) by incubation in 200 mM ammonium bicarbonate at room temperature for 1 h. Buffer exchange into PBS was achieved using a 5 mL disposable de-salting column. Native human α 2 M was converted to the "trypsin-activated" form (α 2 M-T) by incubation with a 5-fold molar excess of trypsin (Worthington Biochemical, Lakewood, NH) for 1 h at room temperature. The Halt protease inhibitor cocktail (Thermo Scientific, Rockford, IL) was then added to inhibit proteolytic activity. Excess trypsin and protease inhibitors were removed by consecutive passes over a 100 kDa centrifugal concentrator (Pall Life Sciences, Ann Arbor, MI). Purified protein contained less than 10 pg of endotoxin per mg of protein, as determined by a commercial assay kit (Limulus Amebocyte Lysate Kinetic-QCL by Cambrex, Walk- 647-conjugated ovalbumin (OVA) (Molecular Probes, Eugene, OR) were prepared as previously described [7] . Molar ratio of incorporation was approximately 3:1 OVA: α 2 M * , as determined by fluorescence quantification.
Time-Dependent Study of OVA Encapsulation into Human α 2 M
A 3-fold molar excess of OVA was incubated at 37˚C with either α 2 M * or α 2 M-T for 0.5 to 24 h. Samples were then immediately analyzed by native PAGE.
Cells and Cell Culture
The MO5 cell line, an OVA-transfected subclone of B16 melanoma, was a kind gift from Dr. Kenneth Rock (University of Massachusetts Medical School, Worcester, MA). MO5 cells were cultured in complete media supplemented with 2 mg/mL G418. Murine splenocytes were harvested and cultured as previously described [7] .
Mice
Female C57/BL6 mice were obtained from Charles River Laboratories (Raleigh, NC). All mice were housed in the Duke University Animal Facility, an AAALAC approved facility. All experiments were conducted under an Institutional Animal Care and Use Committee-approved protocol.
Intradermal Immunization and Tumor Challenge
Prior to tumor challenge, C57/BL6 mice were immunized by intradermal injection into the right ear pinna with 10 μL antigen or PBS, with or without the addition of Preparations of α 2 M * and OVA were kept in separate containers on ice until immediately prior to injection in order to minimize the possibility of in vitro α 2 M * -encapsulation. Mice were subsequently boosted at days 35 and 63, consistent with our previously published immunization protocol [7] . Control groups (n = 5) received intradermal injections of PBS, CpG 1826, or α 2 M * alone. Serum anti-OVA IgG was monitored every 2 weeks by ELISA, as previously described [7] . Mice were injected s.c. in the left flank with 10 4 MO5 tumor cells in Matrigel™ basement membrane matrix (BD Biosciences PharMingen) at week 14. Staining of mouse PBLs with iTAg MHC Tetramer H2-K b SIINFEKL-PE (Beckman Coulter, Fullerton, CA) and Caltag FITC-conjugated Rat anti-Mouse CD8a antibody (Invitrogen Corp., Carlsbad, CA) was performed 2 weeks following tumor implantation, as previously described [7] , in order to quantify the proportion of CD8+ T cells specific for the H2-K b -restricted CTL epitope of OVA, the SIINFEKL peptide (OVA 257-264 ). Tumor diameters were measured using digital calipers, and tumor volume was calculated using the equation V = 0.4 ab The collected fluid samples were analyzed by native PAGE, and incorporation of antigen was measured directly by fluorescence imaging using an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA).
[ 3 H]-Thymidine Proliferation Assay
Splenocytes harvested from mice that had been previously immunized with OVA and CpG 1826 (as above) were pulsed for 6 h with 2.5 μM OVA, either free or codelivered with amine-activated α 2 M * or trypsin-activated α 2 M-T (7.5 μM), in serum-free media. As controls, cells were also pulsed with Con A (5 μg/mL) and α 2 M * containing no antigen. Cells were then washed, resuspended in complete media, loaded at 2.5 × 10 5 cells per well onto a 96-well flat-bottom plate and cultured for 3 d at 37˚C in a humidified 5% CO 2 incubator. Cultured cells were treated with 1 μCi/well [methyl-
3 H]thymidine (PerkinElmer, Waltham, MA) 18 h prior to harvesting. Incorporation of [ 3 H]thymidine was measured using a Tri-Carb 2100 TR liquid scintillation counter (PerkinElmer, Boston, MA).
Statistical Analysis
For in vitro studies, the Student's t-test was performed to determine P values and ascertain statistical signifi-cance between two treatments. For in vivo studies (antibody titers, tetramer staining, and tumor growth), ANOVA was performed, followed by multiple comparison procedures (Tukey) to determine differences between groups. Significance between Kaplan-Meier survival curves was determined by log-rank Mantel-Cox analysis. The level of significance used was 0.05.
RESULTS
Antigen Encapsulation by α 2 M * Occurs Rapidly and Can Be Detected Following as Little as 30 min of Incubation
Consistent with a previous report [8] , maximal incorporation of antigen by α 2 M * occurs after 24 h of incubation at 37˚C (Figure 1) . However, some association of antigen with α 2 M * can be observed at 30 min. This association likely represents covalent antigen incorporation by α 2 M * because it is not observed with proteolyticallyactivated α 2 M-T. Although proteolytic thiol ester cleavage in α 2 M is irreversible, thiol ester cleavage by primary amines can be reversed with heat, allowing the incorporation of new antigens by α 2 M [11] . A small association between OVA and α 2 M-T was observed following 24 h of incubation. Although the mean antibody titers produced by conjugated α 2 M * -OVA were greater than those elicited with OVA and unbound α 2 M * , the difference between these groups was not found to be statistically significant.
Tetramer staining of PBLs was performed 2 weeks following tumor implantation in order to observe expansion of the antigen-specific CD8+ T cell population in these mice (Figure 2(b) ). Mice treated with OVA and unbound α 2 M * with the addition of CpG, however, did elicit expansion of the OVA-specific CD8+ T cell population, which was significant compared to the control groups. Although the OVA with unbound α 2 M * without CpG group appeared to elicit some degree of expansion of the OVA-specific CD8+ T cell population, the tetramer staining population for this group was not significantly greater than that of the control groups (PBS, CpG, or α 2 M * alone). Conjugated α 2 M * -OVA treatment groups appeared to elicit greater expansion of antigen-specific CTLs than the OVA with unbound α 2 M * groups, the differences between these treatment groups were not found to be statistically significant. The greatest expansion of OVA-specific CD8+ T Cell population was observed in the α 2 M conjugated-OVA with the addition of CPG. and unbound OVA, either with or without CpG, was significantly prolonged (P < 0.005) compared to OVA treatment alone (Figure 2(d) ). However, survival of these mice did not differ significantly from that of mice treated with conjugated α 2 M * -OVA.
OPEN ACCESS
Encapsulation of Antigen by α 2 M * Occurs in Vivo in the Setting of Intradermal Injection
We hypothesized that enhanced in vivo immune responses with α 2 M * and OVA co-delivery were the result of in vivo encapsulation of antigen. The conditions of antigen delivery, including the depot effect caused by intradermal injection and the 37˚C environment of the mouse, are similar to the conditions used to successfully incorporate antigen into α 2 M * in vitro [8] . To determine if such in vivo encapsulation of antigen could occur in this setting, we similarly intradermally injected the ear pinnae of mice with a 3:1 molar ratio of OVA:α 2 M * . For comparison, mice were injected with either OVA or α 2 M * alone. After 1.5 h, the mice were euthanized, and the ear pinnae were flushed with 3 × 20 μL PBS. The fluid that was recovered was analyzed by native PAGE (Figure 3) . The detection of fluorescently labeled OVA co-migrating with α 2 M * dimers in these mice confirmed the occurrence of in vivo encapsulation of OVA into α 2 M * . The detection of in vivo α 2 M * encapsulation suggests a mechanism for the enhanced in vivo immune responses discussed above, it was also possible that ligation of the α 2 M * receptor, low-density lipoprotein receptor-related protein 1 (LRP-1)/CD91, in the absence of antigen en-capsulation, may also contribute to this enhanced immunity. To investigate this possibility, splenocytes harvested from OVA-immunized mice were treated for 6 h with OVA and either unconjugated amine-activated α 2 M * or proteolytically-activated α 2 M-T. After 3 days, cell proliferation was measured by [ 
Enhanced Immune Responses with
DISCUSSION
It has been suggested that new generation vaccines will largely consist of purified recombinant proteins [13] . However, formulations of purified protein are frequently poor at eliciting humoral and cell-mediated immunity. Therefore, the development of adjuvants and antigen delivery vehicles that are efficacious, as well as costeffective and practical, is of extreme importance.
The highly conserved proteinase inhibitor α 2 M has received attention in recent years for its ability to entrap diverse macromolecules and target them for rapid receptor-mediated uptake by professional antigen presenting cells. Antigen delivery by α 2 M * elicits 100 to 1000-fold enhanced antibody titers against protein and peptide based vaccines and vaccine candidates, such as hepatitis B surface antigen [3] and the HIV envelope gp120 C4-V3 peptide [4] . Complexes of α 2 M * and trypanosomal proteinases have been shown to activate CD4+ T cells more efficiently than antigen alone [14] and to stimulate the production of antibodies that effectively inhibit activity of the enzyme [15] . Furthermore, our laboratory has recently demonstrated that α 2 M * -encapsulation enhances antigen-specific CTL responses and protection against antigen-presenting tumors [7] . Although these studies have established that α 2 M * -encapsulation can be achieved with relative ease on a small scale, assuming adequate resources and training in biochemical techniques, the large scale production of α 2 M * -antigen complexes may present new challenges. Therefore, achieving enhanced immunologic responses with co-administered α 2 M * , avoiding the steps of in vitro incorporation and isolation of complexes, represents a significant advance for this antigen delivery vehicle.
CONCLUSION
Our findings demonstrate that co-delivery of α 2 M * with unbound antigen can enhance humoral and cellmediated immunity, resulting in improved anti-tumor responses, to similar degree as α 2 M * -antigen complexes prepared in vitro. These enhanced immune responses with α 2 M * co-delivery appear to result from in vivo encapsulation of antigen, rather than a direct effect of ligating LRP by α 2 M * not carrying bound antigen α 2 M * receptors. The capacity of α 2 M * to promote antigen delivery in vivo results from the rapidity with which it encapsulates local macromolecules. Antigens encapsulated by α 2 M * are targeted for rapid receptor-mediated uptake by professional antigen presenting cells, resulting in efficient antigen processing and presentation. We conclude that administration of α 2 M * in the context of a high localized concentration of antigen, such as that which can be achieved with a depot, facilitates antigen delivery and presentation. These findings represent a significant advancement in the use of α 2 M * as an antigen delivery vehicle.
